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Introduction
Vitamin D is a secosteroid hormone, recognised as a neuroprotective factor with a role to play in brain development (Harms 2008 , Eyles 2013 . Vitamin D promotes neurodevelopment, with a range of actions such as promoting cell growth and differentiation, regulation of neurotransmission, immunomodulation and with antioxidant and anti-inflammatory effects.
Vitamin D deficiency has been associated with a range of mental disorders including mood disorders, psychotic disorders, autism and cognitive decline.
Vitamin D physiology
Vitamin D belongs to a group of fat-soluble vitamins. Its primary functions are to aid the intestinal absorption of calcium and phosphate, and on bone ! 4! mineralisation (Holick 2013) . The two main forms of vitamin D are: vitamin D3 or cholecalciferol, which is formed in the skin after exposure to sunlight and ergocalciferol, and vitamin D2, which is obtained by irradiation of plants or plant materials or foods.
Vitamin D levels are influenced by environment and lifestyle. Endogenous synthesis following cutaneous exposure to ultraviolet B radiation is the primary source (see Figure 1) . A smaller proportion is acquired from dietary sources. It is not a widely appreciated fact, but nutritional sources of vitamin D are relatively limited (Holick 2013) . Recently a large meta genome-wide association study (GWAS) involving 31 studies with a total of 79,366 individuals identified genetic variants at three loci (group component (GC), 7-dehydrochlesterol reductase (NADSYN1/DHCR7), and 25-hydroxylase (CYP2R1)) influencing vitamin D levels (Jiang 2018) , though the findings were suggestive of a relatively small heritability rate for vitamin D levels indicating that modifiable environmental factors are the main determinant of vitamin D levels.
INSERT FIGURE 1
UV sunlight stimulation will depend on the season of the year, latitude and skin exposure. Vitamin D levels thus vary seasonally, with deficiency more common in winter and at higher latitudes, reflecting ambient levels of sunlight (Hypponen and Power 2007) as well as in urban settings due to lifestyle choices and lower sunlight exposure (Holick 1995) . People with more pigmented skin need more sunlight to produce vitamin D, so are particularly affected by limited sun exposure; lower levels of vitamin D are consistently observed in Black and Asian populations (Ford 2006) . Older age is associated with lower vitamin D levels, with reduced sunlight exposure and decreased ability to synthesize vitamin D cutaneously with sunlight exposure contributing factors.
Vitamin D deficiency-epidemiology
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Vitamin D deficiency is a global problem; more than a billion people worldwide are believed to have suboptimal levels (Holick and Chen 2008) . A recent systematic review of 195 studies including 168,000 people from 44 countries identified that 37% had mean 25-hydroxyvitamin D (25(OH)D) concentrations lower than <50nmol/L (equivalent to <20ng/ml). Additionally, 6.7% had 25(OH)D levels below 25 nmol/L (equivalent to <10ng/ml)), corresponding to vitamin D deficiency, while only 11% had 25(OH)D levels above 75 nmol/L (equivalent to >30ng/ml), the level classed as sufficient (Hilger 2014) .
Classification of vitamin D status
Serum levels of the main circulating form of Vitamin D, 25-hydroxyvitamin D (25(OH)D), are usually taken as a proxy of vitamin D status (Ross 2011, Holick and Chen 2008) , as it is a more stable compound than the physiologically active form, 1,25(OH)2D3, with higher serum concentrations and a longer half-life (approximately 20 days compared to 7 hours) (Lips 2007) . A systematic review and meta-analysis of observational studies concluded that vitamin D levels were inversely associated with the prevalence of depression (Anglin 2013) . However, the observational nature of the included studies precluded drawing conclusions on a causal relationship (Anglin 2013 ).
There remains a paucity of longitudinal data investigating the relationship between vitamin D and depression. The few existing studies have provided inconclusive results. A recent large-scale population based study of 3251 adults older than 55 investigating long-term associations between vitamin D serum levels and depression identified a cross sectional association between low vitamin and depression, but found no evidence for a longitudinal relationship (Jovanova 2017) . The cross sectional relationship might be expected, as people who are depressed may be less able to engage in outdoor activity and may limit their sun exposure. However, if vitamin D is a risk factor for depression, then we would expect to find that vitamin D concentrations had a longitudinal association with depression and depressive symptoms, which was not found in this study (Jovanova 2017) . This replicated previous longitudinal data which failed to identify a longitudinal association between low vitamin D and depression (Chan 2011 , Toffanello 2014 , though ! 7! was contradictory to findings from two other longitudinal studies (May 2010 , Milaneschi 2010 , which identified a relationship between suboptimal vitamin D levels and the prospective onset of depression.
A meta-analysis of RCTs of vitamin D supplementation as a treatment for depression identified six RCTs with 1203 participants (72% females) including 71 depressed patients (five trials included participants at risk of depression and one trial included patients with depression). There was no significant effect of vitamin D supplementation on depression scores ((standardized mean difference = −0.14, 95% confidence interval =−0.41 to 0.13, P =.32; odds ratio =0.93, 95% confidence interval =0.54 to 1.59, P = .79) (Li 2014 ).
Both these systematic reviews (Anglin 2013 , Li 2014 ) supported the conclusion of previous narrative reviews indicating that no clear causal relationship between suboptimal vitamin D and depression has been identified.
Vitamin D augmentation in depression-trials
Only one small randomised double blind trial of vitamin D3 augmentation of a specific antidepressant medication in depressive disorder has taken place.
Over an eight week period there was a significant improvement in depressive symptoms in those whose fluoxetine 20mg daily was augmented with 1500IU of vitamin D 3 (n=20) compared to placebo (n=20) (Khoraminya 2013) 
Vitamin D and bipolar depression
There has been a single RCT of vitamin D3 augmentation in bipolar depression, with no significant difference in depression symptom scores between those treated with 5000 IU of vitamin D3 daily (n=16) and placebo (n=17) after 12 weeks (Marsh 2017) . This was despite a significantly higher mean increase in vitamin D levels in the augmentation group (9.9 (8.2) ng/ml) compared to the placebo group (1.3 ± 4.3 ng/ml).
The RCTs to date in mood disorders have been limited by small sample sizes, heterogeneity of study populations and vitamin D dosing techniques. These trials have produced inconsistent findings, which provide at best a mild signal for a beneficial effect of vitamin D on mood, but which is far from conclusive. 
Vitamin D and psychotic disorders
Vitamin D insufficiency is highly prevalent in people with schizophrenia and other psychotic disorders (Suetani 2017) . In a cross sectional study of 324 community based people with established psychosis, 86% had suboptimal vitamin D levels (<50ng/ml). In a systematic review, 63% met criteria for Vitamin D deficiency (with the threshold level to define deficiency ranging from 10-40 ng/ml) (Adamson 2017) . 
Vitamin D3 supplementation in schizophrenia
The only randomised trial to date in schizophrenia investigating vitamin D3 augmentation was conducted in a population of clozapine treated patients with treatment resistant schizophrenia (all with vitamin D level <30ng/ml). At 8 weeks, there was no significant difference in psychotic symptoms between those treated with 14,000 IU per week of vitamin D3 (n=24) compared to ! 11! placebo (n=23), though a signal towards improved cognitive performance relating to attention and recall was detected (Krivoy 2017) .
Vitamin D and clinical symptoms in FEP
A major limitation of work so far in FEP is the cross sectional design of most studies, limiting any inference of a causal relationship between vitamin D and clinical status-it may as easily be that the relationship identified between symptoms and low vitamin D, be it in acute psychotic episodes (Yuksel 2014) , or in FEP (Graham 2015) , may be the result of, rather than a cause of psychosis or depression.
We recently investigated the longitudinal relationship between vitamin D levels at time of first contact with services in FEP and clinical symptoms at 12 months, identifying a significant association between higher vitamin D levels at first contact for psychosis and lower negative symptoms and total psychotic symptoms at 12 month follow up (Lally 2018) . This is the first longitudinal assessment of vitamin D levels and associations with psychotic symptoms.
Vitamin D is considered to be neuroprotective, and is postulated to have brain antioxidant properties, reducing oxidative stress (Wrzosek 2013 , Nerhus 2016 , Mitra 2017 by decreasing the production of the oxidant nitric oxide (Garcion 2002) , and increasing the production of antioxidants such as glutathione (Garcion 1996 , Wrzosek 2013 (Lally 2016) . This was the first large scale study to have identified an association between decreased 25(OH)D levels and cardiovascular risk factors in psychotic illnesses. Of interest, we identified associations with hypertension and low 25(OH)D levels, which may be a causally related finding. This is suggested by findings in the general population where low 25(OH)D levels are associated with a higher risk of incident cardiovascular disease and specifically hypertension (Wang 2008) . The strongest correlations with low 25(OH)D levels were with factors related to high body fat (Lally 2016) , which is supported by the findings that those with increased adipose tissue stores (in which vitamin D, being fat soluble, is stored) due to obesity, have lower circulating levels of vitamin D due to this increased storage capacity (Wortsman 2000) .
Vitamin D and bone mineral density (BMD) in psychosis
Osteoporosis is two and half times more common in schizophrenia compared to controls, with 52% having low bone mass (Stubbs 2014 ) and significantly reduced bone mineral density at the lumbar spine (Gomez 2016) . Lifestyle advice should be offered to all patients, and education that the best source for vitamin D is sensible levels of sunlight exposure. Spending 10-15 ! 15! minutes in the sunlight on most days of a week, with face and arms exposed, will suffice to ensure adequate vitamin D levels (Nowson 2012) .
Discussion
Vitamin D deficiency is associated with psychotic disorders, and with depression, as well as with many other chronic physical conditions. The question remains whether vitamin D is a causal factor or a consequence of these illnesses. Over 90% of people with established psychosis have suboptimal vitamin D levels, but depression rates in psychotic disorders are not that high, nor are persisting psychotic symptoms universally prevalent . The observed associations could be due to reverse causation, the illness affecting the vitamin D levels, although our recent prospective paper, while requiring replication, opens the possibility of a direct effect of vitamin D levels on outcomes in early psychosis (Lally 2018) . The evidence that vitamin D deficiency in early life may be a risk factor for later psychosis is somewhat stronger (Eyles 2018) . It may be the case that vitamin D when suboptimal is no longer neuroprotective perhaps due to the loss of its antioxidant or anti-inflammatory effects, leaving the person more vulnerable to emerging illnesses, such as psychosis or depression. In terms of supplementation, randomised trials fail to indicate symptom improvements with vitamin D augmentation in schizophrenia and depression. Nevertheless, vitamin D testing and supplementation has crept into routine medical practice, with the assumption that optimization of vitamin D levels will have longer-term benefits for physical health. However evidence for this is lacking, even in the general population (Manson 2019) .
Conclusion
Vitamin D deficiency has been associated with poorer mental health, depression and with psychotic disorders, as well as with chronic physical conditions. However, the evidence base establishing vitamin D as a potential cause rather than consequence of depression is lacking, with some evidence that developmental vitamin D deficiency may be pertinent to psychosis risk.
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Well-designed clinical trials are needed to further study the relationship between repletion of vitamin D stores and clinical outcomes in patients with depression and schizophrenia before routine testing and supplementation can be recommended. In the meantime, the guidelines for the general population should be followed, bearing in mind that the risks of vitamin D deficiency in those with psychosis and depression are higher than in the general population.
